Korro Bio (KRRO)
NASDAQ:KRRO
Want to see KRRO full AI Analyst Report?
KRRO Stock Chart & Stats
$14.39
-$1.03(-2.68%)
At close: 4:00 PM EST
$14.39
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.20 - $55.89
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$151.87M
Enterprise Value$114.66M
Total Cash (Recent Filing)$113.97M
Total Debt (Recent Filing)$42.88M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Aug 18, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.68
Shares Outstanding14,422,571
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.46
Price to Sales (P/S)11.77
P/FCF Ratio-0.95
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue29.84
Enterprise Value/Gross Profit40.76
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$19.00Price Target Upside32.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.32
Revenue Forecast (FY)$1.68M
Bulls Say, Bears Say
Bulls Say
Pipeline Advancement / R&D StrengthThe selection of KRRO-111 with very high preclinical editing and protein restoration rates indicates a technically competitive RNA-editing program. This materially strengthens Korro's pipeline, raises the likelihood of downstream partnering or milestone revenue, and de-risks long-term clinical development prospects.
High Gross Margin PotentialA reported TTM gross margin near 83% suggests the company's underlying platform and licensing/collaboration revenue mix can be highly margin-accretive as revenues scale. Durable high gross margins support long-term profitability potential once fixed R&D and SG&A are covered.
Manageable Leverage / Near-term Balance-sheet CapacityA modest debt-to-equity ratio and material assets/equity provide near-term funding capacity and lower immediate solvency risk. This balance-sheet headroom supports continued R&D investment and partnership development without immediate distress financing, giving time to execute strategic milestones.
Bears Say
Sustained Cash BurnLarge, persistent negative operating and free cash flow materially increases dependence on external financing. Over time this raises dilution and execution risk, constrains strategic flexibility, and forces management to prioritize near-term funding milestones over long-term development choices.
Small, Declining Revenue BaseA tiny, shrinking revenue base limits the firm's ability to offset operating expenses and demonstrates inconsistent commercialization/partnering traction. This weak top-line reduces visibility on sustainable cash flows and increases reliance on milestone payments or new financing to fund operations.
Large, Persistent Losses And Negative ReturnsDeep operating and net losses with negative ROE reflect structural unprofitability to date. Continued negative returns erode equity and heighten the likelihood of future dilution, making the path to sustained profitability and shareholder value generation longer and more execution-sensitive.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.20 and its highest was $55.89 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $151.87M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Aug 18, 2026 which is in 66 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on May 07, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.727 by $0.037.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -1.31.
How many shares outstanding does Korro Bio have?
Korro Bio has 14,422,571 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.727. Following the earnings report the stock price went down -3.373%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Korro Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (32.04% Upside)
$19.00 (32.04% Upside)
Hedge Fund Trend
Increased
By 409.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-117.86%
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
KRRO Stock 12 Month Forecast
Average Price Target
$19.00
▲(32.04% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―